Prurigo Nodularis: Nemolizumab Efficacy Persists at 52 Weeks ...Middle East

Medscape - News
The encouraging long-term efficacy and safety associated with nemolizumab (IL-31 inhibitor) in prurigo nodularis was supported by a second set of data showing long-term benefit in atopic dermatitis. Medscape Medical News

Hence then, the article about prurigo nodularis nemolizumab efficacy persists at 52 weeks was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Prurigo Nodularis: Nemolizumab Efficacy Persists at 52 Weeks )

Apple Storegoogle play

Last updated :

Also on site :